Erratum: A dominant-negative FGF1 mutant (the R50E mutant) suppresses tumorigenesis and angiogenesis (PLoS ONE (2013) 8:2 (e57927) DOI:10.1371/journal.pone.0057927);A Dominant-Negative FGF1 Mutant (the R50E Mutant) Suppresses Tumorigenesis and Angiogenesis

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Mori, Seiji ^a   Tran, Vu ^b   Nishikawa, Kyoko ^a   Kaneda, Teruya ^a   Hamada, Yoshinosuke ^a   Kawaguchi, Naomasa ^a   Fujita, Masaaki ^b   Takada, Yoko K ^b   Matsuura, Nariaki ^a   Zhao, Min ^b   Takada, Yoshikazu ^b  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 1; MATRIGEL; MUTANT PROTEIN; PROTEIN R50E; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL ASSAY; CHICK EMBRYO; CHORIOALLANTOIS; COLON CARCINOMA; CONTROLLED STUDY; EMBRYO; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MIGRATION INHIBITION; MOUSE; NONHUMAN; RAT; SIGNAL TRANSDUCTION; STABLE EXPRESSION; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULAR RING; WILD TYPE;

EID: 84874555267     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0091599     Document Type: Erratum

References (25)

1. Itoh N, Ornitz DM, (2008) Functional evolutionary history of the mouse Fgf gene family. Dev Dyn 237: 18-27.
2. Lanner F, Rossant J, (2010) The role of FGF/Erk signaling in pluripotent cells. Development 137: 3351-3360.
3. Guillemot F, Zimmer C, (2011) From cradle to grave: the multiple roles of fibroblast growth factors in neural development. Neuron 71: 574-588.
4. Beenken A, Mohammadi M, (2009) The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 8: 235-253.
5. Dorkin TJ, Robinson MC, Marsh C, Bjartell A, Neal DE, et al. (1999) FGF8 over-expression in prostate cancer is associated with decreased patient survival and persists in androgen independent disease. Oncogene 18: 2755-2761.
6. Okunieff P, Fenton BM, Zhang L, Kern FG, Wu T, et al. (2003) Fibroblast growth factors (FGFS) increase breast tumor growth rate, metastases, blood flow, and oxygenation without significant change in vascular density. Adv Exp Med Biol 530: 593-601.
7. Giri D, Ropiquet F, Ittmann M, (1999) Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer. Clin Cancer Res 5: 1063-1071.
8. Presta M, Dell'Era P, Mitola S, Moroni E, Ronca R, et al. (2005) Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 16: 159-178.
9. Hynes RO, (2002) Integrins: bidirectional, allosteric signaling machines. Cell 110: 673-687.
10. Takada Y, Ye X, Simon S, (2007) The integrins. Genome Biol 8: 215.
11. Eliceiri BP, (2001) Integrin and growth factor receptor crosstalk. Circ Res 89: 1104-1110.
12. Mori S, Wu CY, Yamaji S, Saegusa J, Shi B, et al. (2008) Direct Binding of Integrin αvβ3 to FGF1 Plays a Role in FGF1 Signaling. J Biol Chem 283: 18066-18075.
13. Yamaji S, Saegusa J, Ieguchi K, Fujita M, Takada YK, et al. (2010) A novel fibroblast growth factor-1 (FGF1) mutant that acts as an FGF antagonist. PLoS One 5: e10273.
14. Akakura N, Hoogland C, Takada YK, Saegusa J, Ye X, et al. (2006) The COOH-terminal globular domain of fibrinogen gamma chain suppresses angiogenesis and tumor growth. Cancer Res 66: 9691-9697.
15. Feldman J, Goldwasser R, Mark S, Schwartz J, Orion I, (2009) A mathematical model for tumor volume evaluation using two-dimensions. Journal of applied quantitative methods 4: 455-462.
16. Nicosia RF, Ottinetti A, (1990) Growth of microvessels in serum-free matrix culture of rat aorta. A quantitative assay of angiogenesis in vitro. Lab Invest 63: 115-122.
17. Brooks PC, Montgomery AM, Cheresh DA, (1999) Use of the 10-day-old chick embryo model for studying angiogenesis. Methods Mol Biol 129: 257-269.
18. Storgard C, Mikolon D, Stupack DG, (2005) Angiogenesis assays in the chick CAM. Methods Mol Biol 294: 123-136.
19. Ieguchi K, Fujita M, Ma Z, Davari P, Taniguchi Y, et al. (2010) Direct binding of the EGF-like domain of neuregulin-1 to integrins (αvβ3 and α6β4) is involved in neuregulin-1/ErbB signaling. J Biol Chem 285: 31388-31398.
20. Auerbach R, Lewis R, Shinners B, Kubai L, Akhtar N, (2003) Angiogenesis assays: a critical overview. Clin Chem 49: 32-40.
21. Thurber GM, Schmidt MM, Wittrup KD, (2008) Factors determining antibody distribution in tumors. Trends Pharmacol Sci 29: 57-61.
22. Kopchick JJ, Parkinson C, Stevens EC, Trainer PJ, (2002) Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocr Rev 23: 623-646.
23. Schreiber I, Buchfelder M, Droste M, Forssmann K, Mann K, et al. (2007) Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur J Endocrinol 156: 75-82.
24. Saegusa J, Yamaji S, Ieguchi K, Wu CY, Lam KS, et al. (2009) The direct binding of insulin-like growth factor-1 (IGF-1) to integrin αvβ3 is involved in IGF-1 signaling. J Biol Chem 284: 24106-24114.
25. Fujita M, Ieguchi K, Davari P, Yamaji S, Taniguchi Y, et al. (2012) Cross-talk between integrin α6β4 and insulin-like growth factor-1 receptor (IGF1R) through direct α6β4 binding to IGF1 and subsequent α6β4-IGF1-IGF1R ternary complex formation in anchorage-independent conditions. J Biol Chem 287: 12491-12500.